Haemolytic uraemic syndrome (HUS) is a heterogeneous group of diseases that result in a
common pathology, thrombotic microangiopathy, which is classically characterised by the …

SARS-CoV-2 causes a phenotype of pneumonia with diverse manifestation, which is termed
as coronavirus disease 2019 (COVID-19). An impressive high transmission rate allows …

Background Generalized myasthenia gravis (gMG) is a rare, chronic, and debilitating
autoimmune disease. Activation of the complement system by autoantibodies against the …

Introduction Ravulizumab demonstrated efficacy and an acceptable safety profile versus
placebo in the randomized controlled period (RCP) of the phase 3 CHAMPION MG trial in …

There continues to be rapid advancement in our understanding of the pathogenesis of
immune-mediated kidney disease. This progress has culminated in the development of …

Introduction The terminal complement C5 inhibitor ravulizumab has a long elimination half-
life, allowing maintenance dosing every 8 weeks. In the 26-week, double-blind, randomized …

It has long been known that the complement cascade is activated in various forms of
glomerulonephritis. In many of these diseases, immune-complexes deposit in the glomeruli …

Our understanding and management of atypical hemolytic uremic syndrome (aHUS) have
dramatically improved in the last decade. aHUS has been established as a prototypic …

The complement cascade comprises soluble and cell surface proteins and is an important
arm of the innate immune system. Once activated, the complement system rapidly generates …

Ravulizumab, a long-acting complement C5 inhibitor engineered from eculizumab, allows
extending maintenance dosing from every 2–3 weeks to every 4–8 weeks depending on …